Transdermal delivery of β-blockers

Expert Opinion on Drug Delivery

Volumn 3, Issue 3, 2006, Pages 405-418

  Aqil, Mohammed ^a   Sultana, Yasmin ^a   Ali, Asgar ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

blocker; Drug delivery; Penetration enhancer; Transdermal

Indexed keywords

ACEBUTOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOPINDOLOL; BUPRANOLOL; CARDIOVASCULAR AGENT; CARVACROL; CLONIDINE; ESTRADIOL; EUDRAGIT; FENTANYL; GLYCERYL TRINITRATE; LABETALOL; LEVOBUNOLOL; LIDOCAINE; LIMONENE; LINALOOL; MENTHOL; MEPINDOLOL; METOPROLOL; NICOTINE; OXPRENOLOL; OXYBUTYNIN; PINDOLOL; PROPRANOLOL; SCOPOLAMINE; SOTALOL; TESTOSTERONE; TIMOLOL; UNINDEXED DRUG;

ANGINA PECTORIS; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG UTILIZATION; ELECTROPORATION; FATIGUE; FIRST PASS EFFECT; HUMAN; IMPOTENCE; INCIDENCE; INSOMNIA; IONTOPHORESIS; ISCHEMIC COLITIS; LABORATORY; MOTION SICKNESS; NAUSEA; NEEDLE; NONHUMAN; PATIENT COMPLIANCE; PHARMACOLOGICAL PROCEDURES; REVIEW; SKIN IRRITATION; SKIN MANIFESTATION; SKIN PENETRATION; STOMACH DISEASE;

ADMINISTRATION, CUTANEOUS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; PROPANOLAMINES; SOTALOL;

EID: 33646843377     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.3.3.405     Document Type: Review

References (110)

1. REIN H: Experimental electroendosmotic studies on living human skin. Z. Biol. (1924) 81:124-129.
2. BLANK IH: Penetration of low molecular wieght alcohols into skin. I. Effect of concentration of alcohol and type of vehicle. J. Invest. Dermat. (1964) 43:415-420.
3. SCHEUPLIEN R: Mechanism of percutaneous absorption I. Routes of penetration and the influence of solubility. J. Invest. Dermat. (1965) 45:334-345.
4. MICHAELS AS, CHANDRASEKARAN SK, SHAW JE: Drug permeation through human skin: theory and in vitro experimental measurement. AIChE. J. (1975) 21:985-996.
5. Physicians' Desk Reference. DW Sifton (Ed.), Thomson PDR, Montvale, NJ, USA (2003).
6. CID E, MELLA F, LUCHINNI L, CARCAMO M, MONESTERIO J: Plasma concentrations and bioavailability of propranolol by oral, rectal, and intravenous administration in man. Biopharm. Drug Dispos. (1986) 7:559-566.
7. WALLE T, FAGAN TC, CONRAD EC, WALLE UK, GRAFFNEY TE: Presystemic and systemic glucuronidation of propranolol. Clin. Pharmacol. Ther. (1979) 26:167-172.
8. KUNTA JR, GOSKONDA VR, BROTHERTON HO, KHAN MA, REDDY IK: Effect of menthol and related terpenes on the percutaneous absorption of propranolol across excised hairless mouse skin. J. Pharm. Sci. (1997) 86(12):1369-1373.
9. AMNUAIKIT C, IKEUCHI I, OGAWARA K, HIGAKI K, KIMURA T: Skin permeation of propranolol from polymeric films containing terpene enhancers for transdermal use. Int. J. Pharm. (2005) 289:167-178.
10. ZHAO K, SINGH J: In vitro percutaneous absorption enhancement of propranolol hydrochloride through porcine epidermis by terpenes/ethanol. J. Control. Release (1999) 62(3):359-366.
11. HORI M, MAIBACH HI, GUY RH: Enhancement of propranolol hydrochloride and diazepam skin absorption in vitro. II. Drug, vehicle, and enhancer penetration kinetics. J. Pharm. Sci. (1992) 81(4):330-333.
12. KRISHNA R, PANDIT JK: Transdermal delivery of propranolol. Drug Dev. Ind. Pharm. (1994) 20(15):2459-2465.
13. KRISHNA R, PANDIT JK: Carboxymethylcellulose-sodium based transdermal drug delivery system for propranolol. J. Pharm. Pharmacol. (1996) 48(4):367-370.
14. VERMA PR, IYER SS: Controlled transdermal delivery of propranolol using HPMC matrices: design and in vitro and in vivo evaluation. J. Pharm. Pharmacol. (2000) 52(2):151-156.
15. VERMA PR, IYER SS: Transdermal delivery of propranolol using mixed grades of Eudragit: design and in vitro and in vivo evaluation. Drug Dev. Ind. Pharm. (2000) 26(4):471-476.
16. KRISHNA R, PANDIT JK: Comparative bioavailability of propranolol following oral, intravenous and transdermal administration in rabbits. Biopharm. Drug Dispos. (1993) 14(9):785-788.
17. IORDANSKII AL, FELDSTEIN MM, MARKIN VS, HADGRAFT J, PLATE NA: Modelling of the drug delivery from a hydrophilic transdermal therapeutic system across polymer membrane. Eur. J. Pharm. Biopharm. (2000) 49(3):287-293.
18. FELDSTEIN MM, RAIGORODSKII AL, IORDANSKII AL, HADGRAFT J: Modelling of percutaneous drug transport in vitro using skin-imitating carbosil membrane. J. Control. Release (1998) 52:25-40.
19. BARRY BW: Lipid-protein partitioning theory of skin penetration enhancement. J. Control. Release (1991) 15:237-248.
20. GUYOT M, FAWAZ F: Design and in vitro evaluation of adhesive matrix for transdermal delivery of propranolol. Int. J. Pharm. (2000) 204(1-2):171-182.
21. RAO PR, RAMAKRISHNA S, DIWAN PV: Drug release kinetics from polymeric films containing propranolol hydrochloride for transdermal use. Pharm. Dev. Technol. (2000) 5(4):465-472.
22. KTISTIS G, NIOPAS I: A study on the in vitro percutaneous absorption of propranolol from disperse systems. J. Pharm. Pharmacol. (1998) 50(4):413-418.
23. BHATNAGAR S, VYAS SP: Organogel-based system for transdermal delivery of propranolol. J. Microencapsul. (1994) 11(4):431-438.
24. THACHARODI D, RAO KP: Development and in vitro evaluation of chitosan-based transdermal drug delivery systems for the controlled delivery of propranolol hydrochloride. Biomaterials (1995) 16(2):145-148.
25. MUZZARELLI RA, BALDASSARE V, CONTI F: Biological influence of cross-linking on the permeability properties of chitosan membranes. Biomaterials (1988) 9:247-252.
26. MUZZARELLI RA, BIAGINI G, BELLARDINI M, SIMONELLI L, CASTALDINI C, FRATTO G: Osteoconduction exerted by methylpyrrolidinone chitosan used in dental surgery. Biomaterials (1993) 14:39-43.
27. ORIENTI I, DI PIETRA A, LUPPI B, ZECCHI V: Crosslinked polyvinylalcohol hydrogels as vehicles for hydrophilic drugs. Arch. Pharm. (Weinheim). (2000) 333(12):421-424.
28. NAMDEO A, JAIN N: Liquid crystalline pharmacogel based enhanced transdermal delivery of propranolol hydrochloride. J. Control. Release (2002) 82(2-3):223-236.
29. KOBAYASHI I, HOSAKA K, UENO T et al.: Relationship between the amount of propranolol permeating through the stratum corneum of guinea pig skin and after application of propranolol adhesive patches and skin irritation. Biol. Pharm. Bull. (1996) 19(6):839-844.
30. TOUITOU E, CHOW DD, LAWTER JR: Chiral β-blockers for transdermal delivery. Int. J. Pharm. (1994) 104:19-28.
31. TOUITOU E, GODIN B, KOMMURU TR, AFOUNA MI, REDDY IK: Transport of chiral molecules across the skin. In: Chirality in Drug Design and Development. I Reddy, R Mehvar (Eds), Marcel Dekker, Inc., New York, NY, USA (2003):67-99.
32. CORBO M, LIU JC, CHIEN YW: Bioavailability of propranolol following oral and transdermal administration in rabbits. J. Pharm. Sci. (1990) 79(7):584-587.
33. RAO PR, REDDY MN, RAMAKRISHNA S, DIWAN PV: Comparative in vivo evaluation of propranolol hydrochloride after oral and transdermal administration in rabbits. Eur. J. Pharm. Biopharm. (2003) 56(1):81-85.
34. CORBO M, LIU JC, CHIEN YW: Transdermal controlled delivery of propranolol from a multilaminate adhesive device. Pharm. Res. (1989) 6(9):753-758.
35. AHFS Drug information. GK McEvoy (Ed.), American Society of Health-System Pharmacists, Bethesda, MD, USA (2002):1804-1873.
36. Therapeutic Drugs (Volume I and II). C Dollery (Ed.), Churchill Livingstone, Inc., New York, NY, USA (1991).
37. GHOSH TK, HABIB, MJ, CHILDS K, ALEXANDER M: Transdermal delivery of metoprolol. I. Comparison between hairless mouse and human cadaver skin and effect of N-decylmethyl sulfoxide. Int. J. Pharm. (1992) 88:391-396.
38. STOUGHTON RB: Animal models for in vitro percutaneous absorption. In: Animal Models in Dermatology. HI Maibach (Ed.), Churchill-Livingstone, Inc., New York, NY, USA (1975):121-132.
39. SATO K, SUGIBAYASHI K, MORIMOTO Y: Species differences in percutaneous absorption of nicorandil. J. Pharm. Sci. (1991) 80:104-107.
40. AQIL M, SULTANA Y, ALI A: Matrix type transdermal drug delivery systems of metoprolol tartrate: in vitro characterization. Acta. Pharm. (2003) 53(2):119-125.
41. AQIL M, SULTANA Y, ALI A, DUBEY K, NAJMI AK, PILLAI KK: Transdermal drug delivery systems of a β-blocker: design, in vitro, and in vivo characterization. Drug Deliv. (2004) 11(1):27-31.
42. KOMMURU TR, KHAN MA, REDDY IK: Effect of chiral enhancers on the permeability of optically active and racemic metoprolol across hairless mouse skin. Chirality (1999) 11:536-542.
43. VANBEVER R, LECOUTURIER N, PREAT V: Transdermal delivery of metoprolol by electroporation. Pharm. Res. (1994) 11(11):1657-1662.
44. VANBEVER R, LEBOULANGE E, PREAT V: Transdermal delivery of fentanyl by electroporation. I. Influence of electrical factors. Pharm. Res. (1996) 13:559-565.
45. PRAUSNITZ M: Practical assessment of transdermal drug delivery by skin electroporation. Adv. Drug Deliv. Rev. (1999) 35:61-76.
46. HIRVONEN J, MURTOMAKI L, KONTTURI K: Experimental verification of the mechanistic model for transdermal transport including iontophoresis. J. Control. Release (1998) 56:169-174.
47. VANBEVER R, PREAT V: In vivo efficacy and safety of skin electroporation. Adv. Drug Deliv. Rev. (1999) 35:77-88.
48. JADOUL A, BOUWSTRA J, PREAT V: Effects of iontophoresis and electroporation on the stratum corneum. Review of the biophysical studies. Adv. Drug Deliv. Rev. (1999) 35:89-106.
49. GHOSH TK, ADIR J, XIANG SL, ONYILOFUR S: Transdermal delivery of metoprolol. II. In vitro skin permeation and bioavailability in hairless rats. J. Pharm. Sci. (1995) 84(2):158-160.
50. REDDY LH, GHOSH B: Enhancer aided in vitro permeation of atenolol and prazosin hydrochloride through mice skin. Indian J. Exp. Biol. (2001) 39:47-51.
51. CHO CW, SHIN SC: Enhanced transdermal delivery of atenolol from the ethylene-vinyl acetate matrix. Int. J. Pharm. (2004) 287(1-2):67-71.
52. KIM CK, CHI JJ, SHIM SC, SHIM CK: Effect of fatty acids and urea on the permeation of ketoprofen through rat skins. Int. J. Pharm. (1993) 99:109-118.
53. KANDIMALIA KK, KANOKKANNAN N, SINGH M: Optimization of a vehicle mixture for the transdermal delivery of MT using artificial neural network and response surface method. J. Control. Release (1999) 61:71-82.
54. TOUITOU E, GODIN B, KARL Y, BUJANOVER S, BECKER Y: Oleic acid, a skin penetration enhancer, affects langerhans cells and corneocytes. J. Control Release (2002) 80:1-7.
55. KIM J, SHIN SC: Controlled release of atenolol from the ethylene-vinyl acetate matrix. Int. J. Pharm. (2004) 273(1-2):23-27.
56. SHIN SC, CHOI JS: Enhanced bioavailability of atenolol by transdermal administration of the ethylene-vinyl acetate matrix in rabbits. Eur. J. Pharm. Biopharm. (2003) 56(3):439-443.
57. GHOSH B, REDDY LH: Effect of physicochemical parameters on skin permeability of antihypertensive. Indian J. Exp. Biol. (2001) 39(7):710-714.
58. DEMOU JS, SIDHOM MB, PLAKOGIANNIS FM: Comparative in vitro diffusion studies for atenolol transdermal delivery system. Pharm. Acta. Helv. (1994) 68(4):215-219.
59. JAIN GK, KAUL JL, AGRAWAL SS: In vitro transdermal delivery of atenolol using mouse and guinea pig. Indian J. Exp. Biol. (1993) 31(8):691-693.
60. KANIKKANNAN N, SINGH J, RAMARAO P: In vitro transdermal iontophoretic transport of timolol maleate: effect of age and species. J. Control. Release (2001) 71(1):99-105.
61. SONI S, DIXIT VK: Comparison between the iontophoretic and passive transdermal delivery of timolol maleate across human cadaver skin. Pharmazie (1994) 49(1):73-74.
62. O'NEILL CT, DEASY PB: Development and evaluation using hairless mouse skin of a transdermal timolol product. Int. Pharm. (1988) 48:247-254.
63. JI XF, PING QN, LIU GJ, YU ST: The bioavailability of transdermal therapeutic system of timolol. Yao. Xue. Xue. Bao. (1993) 28(8):609-613.
64. DENET AR, PREAT V: Transdermal delivery of timolol by electroporation through human skin. J. Control. Release (2003) 88(2):253-262.
65. FATOUROS DG, BOUWSTRA JA: Iontophoretic enhancement of timolol across human dermatomed skin in vitro. J. Drug Target. (2004) 12(1):19-24.
66. STAMATIALIS DF, ROLEVINK HH, KOOPS GH: Controlled transport of timolol maleate through artificial membranes under passive and iontophoretic conditions. J. Control. Release (2002) 81(3):335-345.
67. STAMATIALIS DF, ROLEVINK HH, KOOPS GH: Delivery of timolol through artificial membranes and pig stratum corneum. J. Pharm. Sci. (2003) 92(5):1037-1039.
68. KANIKKANNAN N, SINGH J, RAMARAO P: In vitro transdermal iontophoretic transport of timolol maleate: effect of age and species. J. Control. Release (2001) 71(1):99-105.
69. WESTER RC, MAIBACH HI: Animal models for transdermal delivery. In: Transdermal Delivery of Drugs (Volume I). AF Kydonieus, B Berner (Eds), CRC Press, Boca Raton, FL, USA (1987):61-70.
70. BOND JR, BARRY BW: Hairless mouse skin is limited as a model for assessing the effects of penetration enhancers in human skin. J. Invest. Dermatol (1988) 90:810-813.
71. SURBER C, WILHELM KP, MAIBACH HI: In vitro skin pharmacokinetics of acitretin: percutaneous absorption studies in intact and modified skin from three different species using different receptor solutions. J. Pharm. Pharmacol. (1991) 43:836-840.
72. SATO K, SUGIBAYASHI K, MORIMOTO Y: Species differences in percutaneous absorption of nicorandil. J. Pharmn. Sci. (1991) 80:104-107.
73. MONTEIRO-RIVIERE NA, BRISTOL DG, MANNING TO, ROGERS RA: Interspecies and interregional analysis of the comparative histologic thickness and laser Doppler blood flow measurements at five cutaneous sites in nine species. J. Invest. Dermatol (1990) 95:582-586.
74. BRONAUGH RL, KRAELING ME, YOURICK JJ, HOOD HL: Cutaneous metabolism during in vitro percutaneous absorption. In: Percutaneous Absorption: Drugs, Cosmetics, Mechanisms, Methodology (3rd Edition). RL Bronaugh, HI Maibach (Eds), Marcel Dekker, New York, NY, USA (1999):57-64.
75. PANCHAGNULA R, STEMMER K, RITCHEL WA: Animal models for transdermal drug delivery. Methods Find. Exp. Clin. Pharmacol. (1997) 19:335-341.
76. LOMBRY C, DUJARDIN N, PREAT V: Transdermal delivery of macromolecules using skin electroporation. Pharm. Res. (2000) 17:32-37.
77. DENET AR, PREAT V: Transdermal delivery of timolol by electroporation through human skin. J. Control. Release (2003) 88(2):253-262.
78. SUTINEN R, PARONEN P, SAANO V, URTTI A: Water-activated, pH-controlled patch in transdermal administration of timolol. II. Drug absorption and skin irritation. Eur. J. Pharm. Sci. (2000) 11(1):25-31.
79. VERMEIJ P, EL SHERBINI-SCHEPERS M, VAN ZWIETEN PA: The disposition of timolol in man. J. Pharm. Sci. (1978) 30:53-55.
80. VLASSES PH, RIBEIRO LG, ROTMENSCH HH et al: Initial evaluation of transdermal timolol: serum concentrations and β-blockade. J. Cardiovasc. Pharmacol. (1985) 7:245-250.
81. KUBOTA K, KOYAMA E, YASUDA K: Skin irritation induced by topically applied timolol. Br. J. Clin. Pharmacol. (1991) 31:471-475.
82. MCCREA JB, VLASSES PH, FRANZ TJ, ZEOLI L: Transdermal timolol: β-blockade and plasma concentrations after application for 48 hand 7 days. Pharmacotherapy (1990) 10:289-293.
83. SUTINEN R, PARONEN P, URTTI A: Water-activated, pH-controlled patch in transdermal administration of timolol. I. Preclinical tests. Eur. J. Pharm. Sci. (2000) 11(1):19-24.
84. BRAIN KR, HADGRAFT J, JAMES VJ, SHAH VP, WALTERS KA, WATKINSON AC: In vitro assessment of skin permeation from a transdermal system for the delivery of oestradiol. Int. J. Pharm. (1993) 89:R13-R16.
85. GAVRAS H, GAVRAS I, BRUNNER HR, LARAGH JH: Effect of a new β-adrenergic blocker, L-bunolol, on blood pressure and on the renin-aldosterone system. J. Clin. Pharmacol. (1977) 17(5-6):350-357.
86. COMMARATO MA, GIARDINO EC, KOPIA GA, KAPLAN HR: Levo-bunolol and propranolol: further evaluation of oral β-blocking activity in conscious dogs. Arch. Int. Pharmacodyn. Ther. (1977) 226(2):205-213.
87. GHOSH TK, GOKHALE RD. CHIAO CS: In vitro assessment of a matrix system of levobunolol. J. Pharm. Pharmacol. (1992) 44(6):512-514.
88. WELLSTEIN A, KUPPERS H, PITSCHNER HF, PALM D: Transdermal delivery of bupranolol: pharmacodynamics and β-adrenoceptor occupancy. Eur. J. Clin. Pharmacol. (1986) 31(4):419-422.
89. 14C-bupranolol in humans, dogs, and rhesus monkeys. Drug Metab. Dispos. (1982) 10(1):51-54.
90. OGISO T, HATA T, IWAKI M, TANINO T: Transdermal absorption of bupranolol in rabbit skin in vitro and in vivo. Biol. Pharm. Bull. (2001) 24(5):588-591.
91. BABU RJ, PANDIT JK: Effect of penetration enhancers on the release and skin permeation of bupranolol from reservoir-type transdermal delivery systems. Int. J. Pharm. (2005) 288(2):325-334.
92. TAKKA S, RAJBHANDARI S, SAKR A: Effect of anionic polymers on the release of propranolol hydrochloride from matrix tablets. Eur. J. Pharm. Biopharm. (2001) 52:75-82.
93. BABU RJ, PANDIT JK: Effect of cyclodextrins on the complexation and transdermal delivery of bupranolol through rat skin. Int J. Pharm. (2004) 271(1-2):155-165.
94. VOLLMER U, MULLER BW, PEETERS J, MESENS J, WILLFERT B, PETERS T: A study of the percutaneous absorption enhancing effects of cyclodextrin derivatives in rats. J. Pharm. Pharmacol. (1994) 46:19-22.
95. LARRUCEA B, ARELLANO A, SANTOYO S, YGARTUA P: Study of the complexation behavior of tenoxicam with cyclodextrins in solution: improved solubility and percutaneous permeability. Drug Dev. Ind. Pharm. (2002) 28:245-252.
96. Martindale: Extra Pharmacopoeia (13th Edition). JE Reynolds (Ed.), The Pharmaceutical Press, London, UK (1993):624-641.
97. DREWE J, MEIER R, TIMONEN U et al.: Pharmacokinetics and pharmacodynamics of a new transdermal delivery system for bopindolol. Br. J. Clin. Pharmacol. (1991) 31(6):671-676.
98. DE MEY C, ENTERLING D: Noninvasive estimates of the inodilatory effects of isoprenaline and their inhibition by transdermally delivered mepindolol in healthy men. J. Cardiovasc. Pharmacol. (1992) 20(3):358-366.
99. SPIEKER C, VETTER H, LIEDTKE R, ZIDEK W, VETTER W: Transdermal β-blocker therapy in essential hypertension. Am. J. Hypertens. (1988) 1(3 Pt 3):199S-200S.
100. SPIEKER C, VETTER W, ZIDEK W, VETTER H: Evaluation of the therapeutic effect of transdermal β-blocker therapy in patients with essential hypertension. Arzneimittelforschung (1989) 39(11A):1512-1514.
101. DE MEY C, ENTERLING D, EDERHOF M, WESCHE H, OSTERWALD H: Transdermal delivery of mepindolol and propranolol in normal man. 1st Communication: study design, clinical and pharmacodynamic aspects. Arzneimittelforschung (1989) 39(11A):1505-1508.
102. DE MEY C, MEINEKE I, ENTERLING D, REHBOCK C, OSTERWALD H: Transdermal delivery of mepindolol and propranolol in normal man. 2nd Communication: pharmacokinetic and neuro-endocrine aspects. Arzneimittelforschung (1989) 39(11A):1508-1512.
103. CONJEEVARAM R, CHATURVEDULA A, BETAGERI GV, SUNKARA G, BANGA AK: Iontophoretic in vivo transdermal delivery of β-blockers in hairless rats and reduced skin irritation by liposomal formulation. Pharm. Res. (2003) 20(9):1496-1501.
104. HIRVONEN J, MURTOMAKI L, KONTTURI K: Effect of diffusion potential, osmosis and ion-exchange on transdermal drug delivery: theory and experiments. J. Control. Release (1998) 56(1-3):33-39.
105. AQIL M, ZAFAR S, ALI A, AHMAD S: Transdermal drug delivery of labetolol hydrochloride: system development, in vitro; ex vivo and in vivo characterization. Curr. Drug Deliv. (2005) 2(2):125-131.
106. TASHIRO Y, SAMI M, SHICHIBE S, KATO Y, HAYAKAWA E, ITOH K: Effect of lipophilicity on in vivo iontophoretic delivery. II. β-blockers. Biol. Pharm. Bull. (2001) 24(6):671-677.
107. MARRO D, KALIA YN, DELGADO-CHARRO MB, GUY RH: Contributions of electromigration and electroosmosis to iontophoretic drug delivery. Pharm. Res. (2001) 18(12):1701-1708.
108. DENET AR, UCAKAR B, PREAT V: Transdermal delivery of timolol and atenolol using electroporation and iontophoresis in combination: a mechanistic approach. Pharm. Res. (2003) 20(12):1946-1951.
109. WILLE JJ, KYDONIEUS A, KALISH RS: Several different ion channel modulators abrogate contact hypersensitivity in mice. Skin Pharmacol. Appl. Skin Physiol. (1999) 12(1-2):12-17.
110. KALISH R, WOOD JA, WILLE JJ, KYDONIEUS A: Sensitization of mice to topically applied drugs: albuterol, chlorpheniramine, clonidine and nadolol. Contact Dermatitis (1996) 35(2):76-82.